Interim report
Page 1
INTERIM REPORT JANUARY 1 - SEPTEMBER 30 , 2021 Biolnvent Q3 BioInvent's CEO : " The powerful combination of Biolnvent's R & D and in - house manufacturing provides invalu able support to our clinical development and facilitates the execution of our current clinical portfolio . The integration of functions , on top of world leading science , makes it possible for us to develop novel treatments for patients suffering from serious diseases . The solid balance sheet and strong , loyal shareholders support us in achieving our goals , " said Martin Welschof . Events in the quarter ( R ) Biolnvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI - 1808 in combination with KeytrudaⓇ ( pembrolizumab ) in patients with advanced solid ● tumors . • Emma Meurling joined Bioinvent as Human Resource ( HR ) Director . Events after the period Biolnvent and Transgene announced that preclinical data for BT - 001 , a novel oncolytic virus delivering an anti - CTLA - 4 antibody for the treatment of solid tumors , will be presented at SITC in November 2021 . • New data on the lead drug candidate BI - 1206 Phase 1 / 2a study in non - Hodgkin's lymphoma ( NHL ) to be presented at the ASH ( American Society of Hematology ) conference December 11-14 . • New production agreement with CRUK to produce additional batch of anti - HER3 antibody . • Prof. Eggermont new member of the BioInvent Scientific Advisory Board . ● Financial information Third quarter 2021 Net sales SEK 3.0 ( 16.3 ) million . ● Loss after tax SEK -62.6 ( -32.9 ) million . Loss after tax per share before and after dilution SEK -1.07 ( -1.00 ) . • Cash flow from operating activities -57.5 ( -31.4 ) million . ● ● January - September 2021 • Net sales SEK 14.5 ( 48.6 ) million . ● Loss after tax SEK -199.7 ( -104.9 ) million . Loss after tax per share before and after dilution SEK -3.79 ( -4.00 ) . Cash flow from operating activities SEK -170.1 ( -91.8 ) million . Liquid funds and long - term investments as of September 30 , 2021 : SEK 1,445.3 ( 642.1 ) million . ● ● ● ( R ) = Regulatory event The information was submitted for publication , through the agency of the contact person set out on page 23 , at 8:00 a.m. CEST on October 28 , 2021 .